Phoenix WinNonlin

Phoenix WinNonlin

Phoenix WinNonlin: The Industry Standard for NCA and PK/PD Modeling and Simulation Phoenix WinNonlin™ is the industry standard for non-compartmental analysis (NCA), pharmacokinetic/pharmacodynamic (PK/PD), and toxicokinetic (TK) modeling. Integrated tools for data processing, post-analysis processing, table creation, graphics, and compliance create an all-in-one collaboration workbench used by scientists, reviewers, medical writers, and quality assurance staff […]

Read More
Topics:

Phoenix

Phoenix PK/PD Modeling and Simulation Software   Certara’s Phoenix® platform is the leading PK/PD modeling and simulation software used worldwide by more than 6,000 researchers at biopharmaceutical companies, academic institutions, and global regulatory agencies, including eleven divisions of the US FDA. Phoenix includes WinNonlin™, the industry standard for non-compartmental analysis (NCA), pharmacokinetic/pharmacodynamic (PK/PD), and toxicokinetic […]

Read More
Topics:

Phoenix 8.1 DEV

Phoenix PK/PD Modeling and Simulation Software Certara’s Phoenix platform is the leading PK/PD modeling and simulation software used worldwide by 6,000 researchers at biopharmaceutical companies, academic institutions, and global regulatory agencies, including eleven divisions of the US FDA. Phoenix extends the winning formula of WinNonlin by combining its trusted algorithms with built-in, easy-to-use graphical user […]

Read More
Topics:

Phoenix WinNonlin DEV

Phoenix WinNonlin 8.1: The Industry Standard for NCA and PK/PD Modeling and Simulation Phoenix® WinNonlin® is the industry standard for non-compartmental analysis (NCA), pharmacokinetic/pharmacodynamic (PK/PD), and toxicokinetic (TK) modeling. Integrated tools for data processing, post-analysis processing, table creation, and graphics create an all-in-one collaboration workbench used by scientists, reviewers, medical writers, and quality assurance staff for […]

Read More
Topics:

Phoenix 8.1

Phoenix PK/PD Modeling and Simulation Software Certara’s Phoenix platform is the leading PK/PD modeling and simulation software used worldwide by 6,000 researchers at biopharmaceutical companies, academic institutions, and global regulatory agencies, including eleven divisions of the US FDA. Phoenix extends the winning formula of WinNonlin by combining its trusted algorithms with built-in, easy-to-use graphical user […]

Read More
Topics:

Phoenix WinNonlin

Phoenix WinNonlin 8.1: The Industry Standard for NCA and PK/PD Modeling and Simulation Phoenix® WinNonlin® is the industry standard for non-compartmental analysis (NCA), pharmacokinetic/pharmacodynamic (PK/PD), and toxicokinetic (TK) modeling. Integrated tools for data processing, post-analysis processing, table creation, graphics, and compliance create an all-in-one collaboration workbench used by scientists, reviewers, medical writers, and quality assurance staff […]

Read More
Topics:

PK/PD Modeling and Simulation

Phoenix: The Most Comprehensive and Widely-used Software for Pharmacokinetic (PK), Pharmacodynamic (PD), and Toxicokinetic (TK) Modeling and Simulation Phoenix®, the industry’s premier PK/PD modeling and simulation software workbench, is used by over 6,000 scientists in 60 countries at nearly 2,000 institutions, including the top 50 global pharmaceutical companies, academic institutes, and research foundations. Regulatory agencies, including 11 divisions […]

Read More
Topics:

Contact Us

Global Sales To better serve your request, please use the “contact us” form on the right. Drug Development Software US – 888-708-7444 Japan – +80 5037869898 Europe – +49 3020143640 Drug Development & Pharmacometrics Consulting US – 973- 729-4450 Simcyp Consortium UK – +44 (0) 114 460 0200 Regulatory Sciences and Software – Synchrogenix US […]

Read More
Topics:

About Our Solutions

Cutting Edge Modeling and Simulation Solutions for Drug Development Drug development has become more complex and multi-layered. New combination therapies require more precise and individualized analyses, new approaches such as “basket studies” evaluate potential disease targets through a new lens, safety issues are more challenging, and comparative effectiveness plays an increasingly important role in “go/no […]

Read More
Topics: